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E
 
xperimental autoimmune encephalomyelitis (EAE) has
served as a prototypic model of T cell–mediated, organ-
specific autoimmune disease, and as a useful model for the
human disease, multiple sclerosis (MS) (1). Frei et al. (2)
demonstrate that in two strains of mice with a double
knockout, where both TNF-
 
 
 
 and LT-
 
 
 
 are inactivated,
that EAE may develop. The disease in these double knock-
out mice progresses in an apparently typical fashion, con-
cordant with what is observed in the usual inbred strains of
mice where EAE is induced: there is clinical paralysis, and
histopathology reveals intense perivascular and parenchy-
mal infiltration with CD4+ T cells and demyelination.
They conclude, and I agree, that the results are surprising,
given the large body of information suggesting that TNF-
 
 
 
and LT-
 
 
 
 are important in the pathogenesis of EAE and
MS. However, before accepting their ultimate conclusion
that, “these results indicate that TNF
 
 
 
 and LT-
 
 
 
 are not es-
sential for the development of EAE,” it is worthwhile to
consider the limitations of the first-generation knockouts
that have been employed in their study. Certain miscon-
ceptions have arisen concerning the interpretation of ex-
periments with these contemporary knockouts. This is espe-
cially true when trying to understand the role of critical
effector molecules like cytokines, in the development of
complex phenotypes, like the paralysis and inflammation
seen in EAE. Many of these cytokine molecules have di-
verse biological activities, and many of the functions of
these molecules can be duplicated by other cytokines.
Thus, in animals with disrupted or “knocked out” cytokine
genes, one may expect many diverse changes in several
physiological processes, and one might find that after all is
done, that another gene and its product can replace the
function of the gene that was disrupted.
 
Contradiction: TNF-
 
 
 
 and LT-
 
 
 
 Are Critical in
the Development of EAE, Yet Disease Occurs in the
TNF-
 
 
 
–LT-
 
  
 
Double Knockout
 
There is abundant evidence that TNF-
 
 
 
 and LT-
 
 
 
 are
critical in the development of EAE, and in the human dis-
ease, MS (3–12). Both TNF-
 
 
 
 and LT-
 
 
 
 mRNA and pro-
tein are in the central nervous system in acute EAE (3–6).
T cell clones, reactive to myelin basic protein, are more ca-
pable of mediating EAE, when they produce higher amounts
of TNF-
 
 
 
 and LT-
 
  
 
(7). Blockade of clinical paralysis in
EAE has been successful with anti-TNF antibodies (8, 9) or
soluble TNF type I receptors (10, 11). Reversal of EAE is
seen with altered peptide ligands of myelin basic protein
that reduce production of TNF-
 
 
 
 (12, 13). Reduction of
TNF-
 
 
 
 with type I phosphodiesterase inhibitors like the
antidepressant, Rolipram, also leads to the reversal of EAE
(14, 15). Relapsing attacks of paralysis in EAE, which can
be induced with superantigens, are blocked with anti-TNF
(16). TNF is produced in high amounts by glial cells in
strains that are susceptible to EAE, but not in resistant
strains (17). Demyelination is mediated in vitro in oligo-
dendroglial cultures by TNF-
 
 
 
 and LT-
 
  
 
(18). Overex-
pression of TNF-
 
 
 
 in the central nervous system leads to
demyelination (19). This experiment in a transgenic mouse
with the TNF-
 
 
 
 transgene expressed in the central nervous
system, stands in contrast to the double knockout mice
used here, where the LT-
 
 
 
 and TNF-
 
 
 
 genes are disrupted
throughout the animal, not only in the central nervous sys-
tem. Injection of TNF-
 
 
 
 can trigger relapses of EAE (20,
21). All these experiments in EAE, reinforce the findings
indicating that TNF-
 
 
 
 and LT-
 
 
 
 play a pathogenic role in
MS: TNF-
 
 
 
 and LT-
 
 
 
 are found in demyelinating lesions
in the brains of MS patients, and increases in TNF can be
seen in the spinal fluid before relapses (22).
 
Reconciliation of the Data On the Role of TNF
 
 
 
 in 
Demyelinating Disease
 
Cytokines may exert several, even opposing effects at
distinct points, both anatomically or temporally during an
immune response. Produced and released naturally during
an immune response, cytokines will be regulated, and their
action will usually only target cells at the site of production.
Conversely, systemic administration of cytokines inevitably
cannot be under such control, and thus adverse rather than
physiologic effects may ensue. Thus, cytokines often pro-
duce paradoxical effects when delivered systemically, rather
than via effector cells at the site of pathology in situ: TNF-
 
 
 
may inhibit demyelinating disease, for instance, in Theiler’s
virus induced demyelination (23). Likewise in EAE, deliv-
ery of TNF-
 
 
 
 by a recombinant vaccinia virus inhibited
EAE (24). Similarly with Th2 cytokines, systemic delivery
of IL-4 worsens EAE (25), while local delivery of IL-4 via
T cell clones ameliorates disease (26).
There are numerous effector molecules in EAE. It is
clear that IL-6 (27), nitric oxide (28, 29), and TNF-
 
 
 
 may
all play a role in the immunopathology of EAE and MS.
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Given the redundant function of these molecules, it is not
surprising that inactivating one or more of them, may still
not influence a change in phenotype.
The remarkable redundancy in cytokine function is ele-
gantly demonstrated in mice with a transgene for a TCR
for myelin basic protein and an inactivated RAG-1 gene.
In these mice EAE still develops without Th1 T cells. Ex-
amination of their brains reveals IL-4 production without
evidence for TNF-
 
 
 
. Thus even without Th1 cytokines,
EAE can still develop with the appearance of Th2 cyto-
kines in active lesions (Lafaille J, J. Van de Keere, J. Baron,
W. Haas, and S. Tonegawa, manuscript submitted for pub-
lication).
Given these intricacies and redundancies in cytokine
pathways, it may not be accurate to claim that TNF-
 
 
 
 and
LT-
 
 
 
 are not essential for EAE in normal animals. As Frei
and colleagues write, “Alternatively, in their absence other
cytokines may compensate for the defect.” (27). I would
support this interpretation, and I would inquire about what
other cytokines were expressed in these inflamed brains.
Were other Th1 cytokines expressed, or were Th2 cytokines
present? Indeed gamma interferon transcripts were found in
the brains of animals showing EAE with TNF-
 
 
 
 and LT-
 
 
 
inactivated. Paradoxically perhaps in inbred mice without
disrupted genes, administration of gamma interferon inhib-
its EAE, while antibody to gamma interferon enhances EAE
(27, 30).
There are major abnormalities in many of the new strains
of mice with disrupted (knocked out) genes using the con-
temporary technology. Often, the genes under study are
inactivated during the entire life of the organism, and are
inactivated throughout the organism. In these TNF-
 
 
 
– and
LT-
 
 
 
–deficient mice there is abnormal spleen architecture,
blood lymphocytosis, absence of lymph nodes, and func-
tional defects in T cell physiology (31). Are these appropri-
ate conditions to study gene function and make conclu-
sions about the role of these genes in autoimmunity?
Perhaps the next generation of knockout animals with
spatial and temporal control of the inactivated gene will be
more useful (32). Wilson and Tonegawa write: “The major
drawback of the current gene-knockout technology, as ap-
plied to the brain, is the lack of regional and temporal spec-
ificity.” (32). Identical problems also confound studies on
immune function with the current knockouts for cytokine
genes, now being used. Work with the current generation
of knockouts in EAE show that disease develops well when
gamma interferon is inactivated (33), when IL-4 is inacti-
vated (34), and when TNF-
 
 
 
 and LT-
 
 
 
 are inactivated (2).
Obviously in these knockout mice other cytokines and
mediators may then assume the functions of the deleted
products of the inactivated genes. Future studies involving
knockouts need to take these issues into consideration.
Given new technologies involving microarrays, it is now
possible to screen for a wide variety of cytokines, chemo-
kines, metalloproteases, adhesion molecules, and other criti-
cal mediators on a single sample of RNA from the brain of
a mouse with EAE (35). Comparison of the array of medi-
ators transcribed in such knockout mice with EAE to other
mice without the disrupted genes, who nevertheless develop
EAE, will give further clues to how alternative pathways
are utilized to achieve a classical phenotype. The concept
that there is a single mediator ultimately causing pathology
in a phenotype as complex as EAE, is probably flawed. The
culmination of a complex sequence of pathological events
results in disease. Studies with the current generation of
knockouts reveal the redundancy of certain mediators, like
TNF-
 
 
 
 and LT-
 
 
 
, in complex pathophysiological events.
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